Lunai Bioworks Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Lunai Bioworks Inc. (LNAI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $6.67 million for the 12-month period ending 2024-06-30, per its 10-K/A filed 2025-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-02-19
- Lunai Bioworks Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $6.67M, a 71.70% increase from fiscal 2023.
- Lunai Bioworks Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $3.89M, a 37.26% increase from fiscal 2022.
- Lunai Bioworks Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $2.83M, a 137.36% increase from fiscal 2021.
- Lunai Bioworks Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $1.19M, a 56.61% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-06-30 | $6.67M 10-K/A · filed 2025-02-19 |
| 2023-06-30 | $3.89M 10-K/A · filed 2025-02-19 |
| 2022-06-30 | $2.83M 10-K · filed 2023-10-02 |
| 2021-06-30 | $1.19M 10-K · filed 2023-02-27 |
| 2020-06-30 | $761.61K 10-K · filed 2021-09-24 |
| 2019-06-30 | $454.64K 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |